SMYD2 and ovarian carcinoma: In ovarian cancer cell lines, increased sub-G1 and cleaved poly(ADP‒ribose) polymerase (PARP) levels were observed after treatment with SMYD2 siRNA and LLY-507, and a synergistic effect with PARP inhibitors was observed, confirming the utility of SMYD2 inhibitors in ovarian cancer49.